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ABSTRACT
Long bones develop via endochondral ossification, a process in which cartilage
precedes bone. During endochondral ossification prechondrogenic cells undergo
proliferation and apoptose as cells of the periosteum differentiate into bone. The process
of endochondral ossification is regulated by a group of endocrine as well as paracrine
molecules that includes bone morphogenetic protein-2 (BMP-2) and parathyroid
hormone-related peptide (PTHrP). Collagens are extracellular matrix molecules that are
present in a spatiotemporal manner during endochondral ossification. Collagen XI alpha
1 (Col11a1) is a minor fibrillar collagen that is alternatively spliced during development
and can result in up to eight different spliceforms. During endochondral ossification,
Col11a1 spliceforms have a distinct expression profile in the growing long bone. The
significance of the different spliceforms has not been characterized. Here, I studied the
effects of BMP-2 and PTHrP on the expression of Col11a1 in pre-chondrogenic mouse
ATDC5 and pluripotent mouse C2C12 cells. I also investigated the role of different
Col11a1 spliceforms in BMP-2-mediated C2C12 osteoblast differentiation. My results
suggest a role for BMP-2 in regulating Col11a1 splicing and expression that includes the
induction of exons 6A, 7, and 8. Further I show that while PTHrP alone did not affect
Col11a1 expression, when combined with BMP-2, PTHrP was able to diminish BMP-2induced Col11a1 expression. In addition, Col11a1 NTD[p6b-7] reduced BMP-2 activity
in C2C12 cells while Col11a1 NTD[p7] did not have any significant effects. Col11a1
NTD[p6b-7] also reduced the expression of alkaline phosphatase and collagen 1 alpha 1
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and increased the expression of Runx2 and osteocalcin while NTD[p7-8] induced the
expression of osteocalcin, Runx2, and collagen alpha 1. When Col11a1 was knocked
down, the expression of BMP-2-induced markers alkaline phosphatase, Runx2,
osteocalcin, and collagen 1 alpha 1 were reduced at 24h post induction with BMP-2,
suggesting a role for collagen XI alpha 1 during early osteoblast differentiation. In
ATDC5 cells, I determined a role for PTHrP in the induction of collagen XI alpha 1
exons 6A, 7, and 8 during early chondrocyte differentiation and exon 6B during late
chondrocyte differentiation. Overall the results of this project show a novel role for
collagen XI alpha 1 in BMP-2-mediated osteoblast differentiation and also suggest a role
for PTHrP in regulating collagen XI alpha splicing and expression during ATDC5
chondrocyte differentiation.
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INTRODUCTION
The skeleton starts forming during the second month of human development.
Initially, mesenchymal cells condense and define the position and basic shape of the
future skeletal element. Once the initial mesenchyme condensations are formed,
depending on the growth factors present in the immediate environment, cells either
differentiate into osteoblasts to form bone or into chondrocytes to form cartilage. Wnt
signaling drives mesenchymal cells to differentiate into osteoblasts. In the absence of
Wnt signaling, SRY (Sex Determining Region Y)-Box 9 (Sox9) levels increase and
mesenchymal cells differentiate into prechondrogenic cells. Once committed,
prechondrogenic cells start producing major cartilage extracellular matrix proteins,
including collagens II and XI. Once prechondrocytes are formed, cartilage starts growing
rapidly in an appositional and interstitial manner, a process known as endochondral
ossification. Interstitial growth occurs as prechondrocytes differentiate into chondrocytes,
which then enlarge and apoptose. As chondrocytes hypertrophy, the perichondrium is
infiltrated with blood vessels and the periosteum is formed. The periosteum houses
mesenchymal cells that upon getting a signal from hypertrophic cells differentiate into
osteoblasts. Bone is formed as osteoblasts start producing a non-mineralizing fibrillar
extracellular matrix, which is then organized into mineralized matrix. Proper bone growth
is dependent upon a complex network of systemic and local growth factors. Sox9 is
essential in the initial commitment into cartilage. Prechondrocytes and cells of the
perichondrium both synthesize Parathyroid hormone related Peptide (PTHrP) to maintain
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chondrocytes in a proliferative state. Prehypertrophic cells on the other hand produce
Indian Hedgehog (IHH), which promotes hypertrophy. Simultaneously, cells of the
periosteum respond to growth factors released by hypertrophic chondrocytes and promote
differentiation of mesenchymal cells into osteoblasts. Bone morphogenetic protein-2
(BMP-2) is crucial for promoting chondrocyte hypertrophy as well as osteoblast
differentiation in the growth plate. Interstitial and appositional growth processes are
linked and the accurate orchestration of different mediators achieves proper bone growth.
Fibrillar collagens are abundant extracellular matrix proteins that provide structure and
support for cells within the growth plate. During endochondral ossification, collagens are
expressed in a tightly regulated spatiotemporal manner. The major fibrillar collagen
present in cartilage is collagen type II, whereas collagen type I is predominantly found in
bone. Collagen XI is a minor yet essential component of collagen fibrils in the
extracellular matrix. Collagens are formed as three procollagen chains come together and
form a heter- or homo-trimer in the extracellular matrix. Collagen XI alpha 1 undergoes
alternative splicing during development and the different spliceforms show a distinct
spatiotemporal expression pattern. My goal in this project was to characterize the
expression of collagen XI alpha I alternative spliceforms in mouse chondrocytes and
pluripotent stem cells. Further, I assessed the effects of two essential growth factors
PTHrP and BMP-2 on collagen XI expression during endochondral ossification. I
hypothesized that PTHrP and BMP-2 regulate collagen XI alpha 1 expression.
To test my hypothesis, I used two different cell models of pluripotent mouse
C2C12 cells and prechondrogenic mouse ATDC5 cells to assess PTHrP effects on the
expression of collagens XI utilizing quantitative real-time PCR. My findings indicate that
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PTHrP regulates collagen XI alpha 1 spliceform expression during chondrogenesis. I also
show that PTHrP alone does not change the expression of collagen XI alpha 1 in
pluripotent C2C12 cells.
Further, I used the mouse pluripotent C2C12 cells and assessed the role of BMP-2
in collagen XI alpha 1 expression during osteoblast differentiation. The results of this
study clearly show that BMP-2 regulates collagen XI alpha 1 expression and that
collagen XI is essential for canonical BMP-2-induced signaling and thus osteoblast
differentiation in C2C12 cells.
In conclusion, my work here shows that 1) continuous treatment of pluripotent
C2C12 cells with PTHrP does not affect collagen XI expression; 2) PTHrP changes the
expression of collagen XI spliceforms during ATDC5 chondrogenesis in vitro; and 3)
Collagen XI alpha 1 spliceforms regulate osteoblast differentiation in a BMP-2dependent manner.
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Abstract
Collagen XI is an extracellular matrix protein required for embryonic
development with a role in both nucleating the formation of fibrils and regulating the
diameter of heterotypic fibrils during collagen fibrillar assembly. Although found in
many different vertebrate tissues throughout the body, Col11a1 is best known for its role
in cartilage during endochondral ossification. To further understand the function of
Col11a1 in the process of bone formation, we compared skeletal mineralization in
wildtype (WT) mice and Col11a1-deficient mice. Overgrowth of the periosteal bone
collar of the developing long bones was observed in the case of Col11a1-deficient mice
compared to WT littermates. The overgrowth was observed on the outside surface of the
bone. To investigate the role of Col11a1 in osteoblast differentiation, we analyzed the
regulation of Col11a1 expression in multipotent C2C12 cells. We found that BMP-2 and
PTHrP regulate both the level of expression as well as the pre-mRNA splicing of
Col11a1. BMP-2 promoted the inclusion of alternatively spliced exons 6A and 8 of the
variable region; however, PTHrP inhibited this effect. While Col11a1 knockdown in preosteoblasts initially reduced the BMP-2-induced expression of osteoblast markers
osteocalcin (OCN), runt-related transcription factor 2 (Runx2), alkaline phosphatase
(ALP), and Collagen I alpha I (Col1a1), at later time points, the opposite effect was
observed, and the knockdown of Col11a1 promoted the BMP-2-induced expression of
osteoblast markers. Introduction of recombinant Col11a1 fragments during osteoblast
differentiation also osteoblast-specific isoforms of recombinant Col11a1 promoted BMP
signaling. In contrast, chondrocyte-specific recombinant isoform Col11a1 [p6b-7]
inhibited BMP-2-stimulated expression of osteoblast markers and BMP activity. Lastly,
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Col11a1 regulated C2C12 proliferation in a spliceform-specific manner. These results
show for the first time that Col11a1 expression and alternative splicing is regulated by
BMP-2 and suggests a novel role for Col11a1 spliceforms in osteoblast differentiation
and bone collar formation during endochondral ossification.
Keywords: Col11a1, BMP-2, C2C12, PTHrP, alternative splicing, gene expression.
Graphical abstract:

Highlights
•
•
•

Col11a1-deficient mice exhibit increased bone collar thickness compared to
wildtype.
BMP-2 and PTHrP regulate the expression of Col11a1 during osteoblast
differentiation.
Col11a1 isoforms regulate the BMP-2-induced differentiation of C2C12 cells into
osteoblasts.
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Introduction
The skeleton develops via processes of endochondral and intramembranous
ossification. Long bones elongate by means of interstitial growth and widen via
appositional growth. Interstitial growth of long bones occurs via endochondral
ossification in which cartilage is replaced by bone whereas appositional growth occurs as
progenitor cells of the periosteum differentiate into osteoblasts and deposit bone. The
process of bone development starts during fetal life and persists until puberty when
growth ceases. In a typical long bone, endochondral ossification occurs at the growth
plate, which consists of specific zones (Figure 1A) [1].

Figure 1.
Endochondral ossification in the growth plate starts with
prechondrocytes that undergo initial differentiation into chondrocytes. Proliferative
chondrocytes apoptose and cartilage is replaced by bone as mesenchymal stem cells of
the periosteum differentiate into osteoblasts. PTHrP and BMP-2 are key plays in the
process of endochondral ossification. While PTHrP is widely known for its role in
maintaining chondrocytes proliferation and inhibiting terminal differentiation, BMP-2 is
an inducer of chondrocyte hypertrophy as well as osteoblast differentiation via the
canonical SMAD signaling pathway.
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The resting zone contains pre-chondrocytes that differentiate into mature
chondrocytes forming the proliferative zone. Proliferating chondrocytes then align into
columns, terminally differentiate into hypertrophic chondrocytes, and undergo apoptosis.
As hypertrophic chondrocytes apoptose, pre-osteoblast progenitor cells of the periosteum
differentiate into osteoblasts, the newly formed bone tissue is innervated, blood vessels
infiltrate, and calcification occurs. The highly dynamic environment of the growth plate
involves a complex network of hormones, paracrine molecules, and growth factors that
work together to facilitate processes of cell proliferation and differentiation that lead to
proper tissue development.
Collagens are abundant extracellular matrix proteins that maintain tissue structure
and control the environment in which cells find themselves [2]. Mutations in collagen XI
have been linked with rare and detrimental human diseases including autosomal
dominant Marshall’s and Stickler syndromes, the more severe autosomal-recessive
fibrochondrogenesis, and otospondylomegaepiphyseal dysplasia (OSMED) [3–8]. In
cartilage, mature collagen XI protein consists of three different alpha chains: Col11a1,
Col11a2, and Col11a3 (an overglycosylated form of Col2a1). However, in bone, a
collagen V/XI hybrid molecule constitutes the minor fibrillar collagen, consisting of
Col5a1, Col5a2, and Col11a1. Targeted mutations of Col11a1 in mice closely reflect
characteristics of the human diseases. Mice lacking Col11a1 die neonatally and exhibit a
phenotype that includes facial dysmorphism and wider but shorter metaphyses in the long
bones, suggesting a role for Col11a1 in proper growth plate development [9–11]. While a
direct effect on growth plate cartilage has been defined, the consequences of absent or

10
reduced levels of Col11a1 expressed by osteoblasts has not been investigated. Col11a2
null mice exhibit a milder cartilage phenotype similar to OSMED patients [12, 13].
The Col11a1 alpha chain of collagen XI contains a non-collagenous amino
terminal domain (NTD) composed of an amino propeptide (Npp) and a variable region
(VR) [14, 15] (Figure 2 ).

Figure 2.
The variable region within the NTD domain of collagen XI alpha 1
undergoes alternative splicing that can result in several different isoform. Each
spliceform is expressed in a distinct spatiotemporal manner during development. The
exact function of alternative splicing in collagen XI alpha 1 is yet to be determined
(Adapted from [19]).
The NTD is found on the surface of heterotypic collagen fibrils and sterically
hinders further addition of collagen molecules, thus regulating fibril diameter [16, 17].
Interestingly, alpha chains of collagen XI undergo alternative splicing. Col11a2 splice
variants quickly converge to produce a single splice isoform during development [18].
Conversely, the variable region of Col11a1 undergoes alternative splicing in a
spatiotemporal manner and the different spliceforms persist as mature proteins in the
ECM, suggesting a role in maintaining or directing matrix events by not only mediating
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fibrillogenesis but also by other mechanisms such as interaction with other extracellular
matrix molecules [19–22].
Materials and Methods
Mice
The embryos used in this study were provided by Dr. Robert Seegmiller (Brigham
Young University). The mice were housed and euthanized as approved by the Institute of
Animal Care and Use Committee of Brigham Young University. All embryos used in this
study were at embryonic day 17.5. A total of six wildtype (WT) (+/+) and three
homozygous (-/-) on a C57Bl6 background were analyzed.
Micro-CT Analysis
Embryos were scanned with a SkyScan 1172 high-resolution micro-CT scanner
(MicroPhotonics, Aartselaar, Belgium) to generate data sets with a 1.7 μm3 isotropic
voxel size using an acquisition protocol that consisted of X-ray tube settings of 60 kV
and 250 μA, exposure time of 0.147 seconds, six-frame averaging, a rotation step of
0.300 degrees, and associated scan times were approximately 7 hours. Following
scanning, two-dimensional reconstructions were used to produce 6000 serial 4000 x 4000
pixel cross-sectional images. Three-dimensional models were reconstructed using a fixed
threshold to analyze the mineralized bone phase using ImageVis 3D software (University
of Utah, Center for Integrative Biomedical Computing, Salt Lake City, UT). A Gaussian
filter (σ=1.0, kernel=3) was used to remove high frequency noise followed by an adaptive
threshold to segment the 3D images, which were visually checked to confirm inclusion of
complete volume of interest.
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Gross geometric measurements were performed using Skyscan CT Analyzer
(CTAn) Software (MicroPhotonics, Aartselaar, Belgium). Comparisons of shape and
cross-sectional area were conducted for long bones. CTAn was used to determine
trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation
(Tb.Sp). Bone volume (BV) and bone surface (BS) were calculated based on the
hexahedral marching cubes volume model of the binarized objects within the volume of
interest and the faceted surface of the marching cubes volume model, respectively. Total
tissue volume (TV) was defined as the volume-of-interest. Trabecular bone volume
fraction (BV/TV) was calculated from BV and TV values. Cross-sectional
reconstructions were color-coded according to three density ranges: high-density range
(white), intermediate-density range (blue), and low-density range (green).
Cell Culture and Differentiation
The mouse pluripotent cell line, C2C12 was purchased from ATCC and
maintained in DMEM (Sigma Chem. Co., St. Louis, MO) supplemented with 10% fetal
bovine serum (FBS) (GIBCO, Grand Island, NY) and antibiotics (100 units/mL of
penicillin-G and 100 μg/mL streptomycin). Cells were kept at 37°C in a humidified
atmosphere of 5% CO2 in air. To differentiate C2C12 cells into osteoblasts, cells were
plated at 2 x 104 cells/cm2 in DMEM supplemented with 5% FBS, 100U/mL penicillin
and 100 μg/mL streptomycin and recombinant human BMP-2 (300 ng/mL) (R&D
Systems, Minneapolis, MN). Control cells were kept in DMEM supplemented with 5%
FBS and antibiotics. Medium was changed every 72 hours and supplemented with fresh
BMP-2. For BMP-2 and PTHrP experiments, cells were treated with BMP-2 for five days
after which PTHrP (10-7 M) (Sigma Aldrich; St. Louis, MO) was added on day 5 for 24
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hours, and RNA was harvested on day 6. For recombinant Col11a1 experiments, DNA
encoding fragments including exons 2-5, 6B, 7, 8, and 9 were amplified, ligated into
expression vectors and expressed as previously described [17]. Recombinant proteins
were purified, refolded, and characterized as previously described [17, 61]. Col11a1 Nterminal fragments were added to C2C12 cells in culture at a concentration of 10 – 60
µg/mL.
Transfection of Cells with Small Interfering RNA
C2C12 cells were grown to 70-80% confluency. Media was then removed and
cells were rinsed with Phosphate Buffer Saline (PBS) twice and 2 mL of serum-free
DMEM was added into each well of a 6-well plate. Col11a1 or SMAD4 siRNA and
scrambled control siRNA (10 μM) (Life Technologies, Carlsbad, CA) were diluted in 300
μL serum free OPTIMEM (Life Technologies, Carlsbad, CA) and mixed with nine
microliters of RNAiMAX Lipofectamine (Life Technologies, Carlsbad, CA) diluted in
300 μL serum-free OPTIMEM. The mixture was incubated at room temperature for 15
min and then 250 μL of mixture was added into each well of a 6-well plate that already
contained 1.75 mL of serum-free DMEM. Cells were incubated with siRNA-containing
medium for 24 hours at 37°C in a humidified chamber containing 5% CO2. The final
concentration of the siRNA was 15 nM. A fluorescent siRNA oligonucleotide (siGLO,
Dharmacon, Lafayette, CO) was used to confirm efficient delivery of siRNA to
71% ± 5.1 (SD) of the cells. After treatment, RNA was extracted as described below to
confirm Col11a1 knockdown and to determine the expression levels of osteoblast
markers. Scramble control siRNA experiments were carried out in an identical manner to
account for any non-specific effects. Cells were treated with BMP-2 (300 ng/mL) for 24h
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and 72h after the 24h transfection to analyze the effect of diminished Col11a1 levels on
BMP-2 signaling activity. For BMP-2 treatment, after the 24h Col11a1 siRNA
transfection, media was replaced with DMEM containing 5% FBS and BMP-2 (300
ng/mL) and incubated for 24h and 72h. RNA was extracted as described below.
Semi-Quantitative Polymerase Chain Reaction
Total RNA was extracted from cells using TriZol (Gibco-BRL; Grand Island,
NY) and 2 μg of RNA was used to synthesize cDNA using High-Capacity cDNA
Reverse Transcription Kit with RNase inhibitor (Life Technologies, Carlsbad, CA).
Twenty-five microliter PCR reactions were prepared using 12.5 μL GoTaq Colorless
Master Mix (Promega, Madison, WI), 1 μL of each forward and reverse primer (10 μM),
3 uL undiluted cDNA, and 7.5 uL nuclease-free water. Samples were amplified for 32
cycles, with denaturation at 95°C (3 min), annealing at 57°C (1 min), and extension at
72°C (30 sec). Col11a1 forward primer was designed to anneal within exon 5 and the
reverse to anneal within exon 9, flanking the variable region: 5’- CAG GAG CCG CAC
ATA GAT GAG-3’ (forward), 5’- TTT CTC TCC ATA TGC GCC AT-3’ (reverse),
generating a defined set of PCR products reflecting the alternative splicing patterns of the
specific cell type. To account for any difference in the amount of RNA, glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was chosen as endogenous control. The
amplification products were separated by electrophoresis through 4% Nusieve 3:1
Agarose (Lonza, Basel, Switzerland) gels according to manufacturer’s instructions and
visualized under UV light after staining with ethidium bromide.
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Primer Design and Quantitative Real-Time PCR
Primers were designed for each exon using Primer Blast (NCBI) (Table 1). Realtime PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems,
Life Technologies; Carlsbad, CA). Each 20 μL PCR reaction consisted of 10 μL SYBR
Green PCR Master Mix, 500 nM of each forward and reverse primer, and 1 μL of
undiluted template cDNA plus nuclease-free water. Targets were amplified using an
Eppendorf real-time PCR Mastercycler as following: 50°C (2 min), 95°C (10 min)
followed by 40 cycles of 95°C (15 sec) and 60°C (1 min) followed by one cycle of 72°C
(1 min). Expression levels were quantified relative to housekeeping gene levels of
expression and presented as 2-ΔCt values to reflect the ratio of expression level of the gene
of interest to that of the housekeeping gene. PCR products were separated by
electrophoresis through 4% Nusieve 3:1 Agarose (Lonza, Basel, Switzerland) to verify
that the primer pair produced a single product of the expected size. A ‘no-template’
control was also included in the assay substituting water for template as well as a control
omitting reverse transcriptase to control for the possibility of genomic DNA
contamination.
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Table 1:
Real-time PCR primers were designed to amplify different Col11a1
exons within the variable region of the NTD using NCBI Primer Blast. Primers were
purchased from Integrated DNA Technologies and resuspended in nuclease-free
water. All primers were used at Annealing temperature of 60 °C. For maximum
efficiency, PCR amplicon sizes were kept below 200bp and products were ran
through agarose electrophoresis to validate amplification.
GENE
ALP
COL1A1
COL11A1 e6A
COL11A1 e6B
COL11A1 e7
COL11A1 e8
OSTEOCALCIN
PPIA
RUNX2

SENSE PRIMER
GTGCCCTGACTGAGGCTGTC
GCATGGCCAAGAAGACATCC
AGGCTGAGAGTGTAACAGAGA
GTTCACATCCCCCAAATCTGA
GGAACAATGGAACCTTACCAGAC
AGGAGTAGACGGCAGGGATT
CCGGGAGCAGTGTGAGCTTA
CGCGTCTCCTTCGAGCTGTTTG
GTGCGGTGCAAACTTTCTCC

ANTISENSE PRIMER
GGATCATCGTGTCCTGCTCAC
CCTCGGGTTTCCACGTCTC
TCTGTTTGTGCTACTGTTTCTTCA
CCCCTAGTTTGGCTTTGGCT
ATTCGATCCTGATACCCGCC
GGAGGTCGTAGTCCTTTCTTCA
TAGATGCGTTTGTAGGCGGTC
TGTAAAGTCACCACCCTGGCACAT
AATGACTCGGTTGGTCTCGG

Western Blot Analysis
To confirm SMAD phosphorylation upon BMP-2 treatment, C2C12 cells were
plated at 2 x 104 cells/cm2 and grown overnight. The next day, medium was changed to
DMEM containing 5% FBS and BMP-2, and incubated for 30 minutes. Cells were then
rinsed twice with cold PBS and lysed using 250 μL of cold M-PER lysis buffer (Pierce,
Rockford, IL) containing protease and phosphatase inhibitors (Halt Protease InhibitorTM,
Pierce, Rockford, IL). A 25 μl aliquot was used to determine protein concentration using
a BCA assay (Bio Rad; Hercules, CA). Twenty micrograms of protein samples were
combined with NuPAGE LDS sample buffer and β-mercaptoethanol (Life Technologies;
Carlsbad, CA) and incubated at 70°C for 10 minutes. Proteins were then separated by 412% SDS-PAGE gradient gel and transferred to nitrocellulose membranes using iBlot®
7-minute iblotting system (Life Technologies; Carlsbad, CA). Membranes were blocked
for 1 hr at room temperature using SuperBlock solution (Life Technologies, Carlsbad,
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CA), washed 3 x 5 min with 10 mM Tris, pH 8 containing 150 mM NaCl, and 0.05%
Tween-20 (TBST) while gently rocking and probed with antibodies as described (Table
2) overnight at 4°C. After 3 x 5 min washes with TBST, horseradish peroxidaseconjugated donkey anti-rabbit IgG (1:5000 dilution in blocking buffer, Cell Signaling,
Danvers, MA) was added for 1 hr at room temperature. Blots were then washed 3 x 5 min
with TBST and incubated in SuperSignal West Femto Maximum Sensitivity
SubstrateTM (Pierce, Rockford, IL) for 1 min and exposed for 5 min on a Kodak Imager
4000R imaging system. Constant substrate concentration was achieved by acquiring
images while the nitrocellulose membrane was completely submerged in ECL solution.
ECL images were taken in the native format using the system's standard software
KODAK and exported to 16-bit TIFF format. Analysis of ECL images was performed
using the public domain ImageJ program (developed at the National Institutes of Health
and available at http://rsb.info.nih.gov.libproxy.boisestate.edu/ij/), using the “Gel
Analysis” functions. Background correction was done using “background subtractor”
tool. Integrated Density Value (IDV) of each band was used to quantify the signals.
Table 2:
Antibodies were purchased from Cell Signaling and used at the
indicated dilutions in blocking buffer overnight at 4°C.
NAME
Beta-Actin
Smad1
(D59D7)
PhosphoSmad1/5
(41D10)

COMPANY
Cell Signaling
Cell Signaling
Cell Signaling

CAT#
4967
6944
9516

ISOTYPE
Rabbit
Rabbit IgG
Rabbit IgG

DILUTION
1:5000
1:1000
1:1000

MW
45kDa
60kDa
60kDa

SPECIFICITY
Polyclonal
Monoclonal
Monoclonal
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Immunofluorescence
C2C12 cells were plated on sterile glass coverslips in the presence and absence of
BMP-2 (300 ng/mL). Media was removed and cells were rinsed twice with PBS. Cells
were then fixed with 1:1 ice-cold acetone:methanol for 15 min and rinsed twice with
PBS. Coverslips were then washed 3 x 5 min with PBS while gently rocking and then
blocked with 2% BSA for 1 hour at room temperature. Antibodies specific for SMAD1
and Phospho-SMAD1/5/8 were used at the indicated dilutions (Table 2) in 0.5% BSA in
PBS (PBB) and coverslips were incubated at 4°C overnight while gently rocking. Cells
were subsequently washed 5 x 5 min in PBB. A Rhodamine (TRITC)-conjugated
AffiniPure Donkey Anti-rabbit IgG (2.5 μg/mL) (Jackson ImmunoResearch Laboratories)
in PBB was added to the cells and incubated at room temperature in the dark for 1 hour.
Coverslips were then washed 5 x 5 min with PBB and mounted on slides using
ProLong® with DAPI (Life Technologies; Carlsbad, CA).
Confocal Microscopy
Images were acquired using an LSM Meta 510 scanning confocal microscope
(Zeiss, Germany) and ZEN 2009 imaging software (Carl Zeiss, Inc., Thornwood, NY).
We used a pinhole of 1.5 Airy units and objective of 63x oil (NA 1.4). Excitation was
provided by the 405 nm line of an Argon laser for DAPI and the 543 nm line of a HeNe
laser for Rhodamine red-X. Images were acquired as confocal stacks (7-12 optical
sections) with an optical section separation (z-interval) of 1.180 μm. Optical sections
were acquired at a digital size of 512 x 512 pixels and averaged 4 times to reduce noise.
Equivalent settings, including pinhole, filters and bandpass were used for all images.
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Luciferase Reporter Assays
To determine the effect of Col11a1 on BMP activity, cells were plated at 65,000
cells/well of a 24-well plate and incubated overnight. The following day, cells were
washed twice with PBS and transfected with LT1 liposomes (Mirus, Madison, WI)
containing 10 ng/well of CMV β-galactosidase control plasmid and 300 ng/well of BMP
reporter element luciferase plasmid (a kind gift from Dr. Allan Albig, Boise, ID) for 24
hr. In designated experiments, cells were also transfected with 14 ng/well of Silencer
Select Col11a1 siRNA (Life Technologies; Carlsbad, CA). The next day, cells were
washed with PBS and medium was changed to DMEM supplemented with 5% FBS and
treated with Col11a1 recombinant protein fragments and BMP-2 (300 ng/mL) for 24 hr.
The following day, C2C12-BRE-luc cells were lysed in Reporter Lysis Buffer (Promega,
Madison, WI) and frozen overnight. Lysates were then collected and enzyme activity was
measured using the Luciferase Assay System and β-Galactosidase Enzyme Assay System
(Promega, Madison, WI). Enzyme activities were measured in a microplate luminometer.
The ratio of luciferase to β-galactosidase activity was calculated, and fold-induction was
determined relative to control. Each data point represents the mean of results from three
independent transfections.
WST-1 Proliferation Assay
C2C12 cells were plated at a density of 5 x 103 cells/100uL of growth medium in
96-well plates and grown overnight at 37°C. The next day, cells were rinsed twice with
PBS and then treated with fresh medium containing Col11a1 recombinant protein
fragments for 24 hr, 48 hr, and 72 hr. At each time point, ten microliters of WST-1
reagent (Clontech, Mountain View, CA) was added to each well and cells were incubated

20
for an additional 2 hr at 37°C in the dark. As a control, WST-1 was also added to empty
and untreated wells to establish a blank baseline. The absorbance was measured using a
BioTek microplate reader at a test wavelength of 450 nm and a reference wavelength of
630 nm.
Results
Col11a1-Deficient Mice Exhibit Overgrowth of Bone Collar
Measurements obtained from X-ray μCT images indicated that the mineralizing
portion of Col11a1-deficient mice long bones were an average of 41% shorter than the
WT humerus and femur, which was in agreement with previously reported results
obtained from whole embryos stained with Alizarin red and Alcian blue (Table 3).
Table 3:
Col11a1-/-

Genotype
WT
Col11a1 -/% difference

Structural indices for humeri are reported as mean +SD for WT and

Length
(µm)
2409 + 33.6
1422 + 65.5
41.0
p < 0.0001

Proximal
Metaphysis
diameter (µm)
806 + 16.9
930 + 38.4
15.4
p < 0.05

Diaphysis
diameter
(µm)
592 + 11.6
735 + 37.4
24.2
p < 0.05

Distal Metaphysis
diameter (µm)
528 + 15.2
778 + 86.1
47.4
p < 0.05

The bones of the Col11a1-deficient mice were wider at all points along the length
(Figures 3A and 3B) and on average were 24% wider at the diaphysis, 15% wider at the
proximal metaphysis, and 47% wider at the distal metaphysis (Table 3). Interestingly, the
Col11a1-deficient long bones displayed an overgrowth of mineralized tissue on the outer
surface of the bone collar (Figures 3C and 3D).
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Figure 3.
Cross-section of humeri at diaphysis, distal, and proximal
metaphyses. Mineralized tissue was assigned a color dependent upon three density
ranges: low density range (green), intermediate density (blue), and high density (white).
Col11a1-deficient humerus was wider and more cylindrical than WT. C-D) Trabecular
bone was more dense in Col11a1-deficient mice compared to WT at proximal
metaphysis. Trabecular bone is less dense in Col11a1-deficient mice compared to WT at
distal metaphysis. Bone collar is less dense but thicker in Col11a1-deficient mice
compared to WT littermate. Scale bars = 0.5 mm. C-D) Histological differences in the
humeri of WT and Col11a1-deficient mice. Trichrome staining was used to identify
mineralized tissue (green), compared to cartilage tissue (blue). Proliferative and
hypertrophic zone of the growth plate in Col11a1-deficient mice showed altered cellular
density, cell size, and organization within the cartilage. Scale bar A and B = 0.5 mm;
scale bars C, D, E, and F = 0.1 mm.
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Trabecular thickness, trabecular separation, and trabecular percent bone volume
were increased in the forelimb bones of the Col11a1-deficient mice compared to
wildtype. Analysis of microarchitectural indices at the proximal metaphysis of the
humerus showed differences in trabecular thickness (92% increase in Tb.Th), trabecular
separation (17% increase in Tb.Sp), and trabecular percent bone volume (73% increase in
BV/TV) in the absence of Col11a1 expression. No significant difference was detected for
isotropy values or structure model index, indicating similar relative prevalence of rods
and plates in the three-dimensional structure of the trabecular bone for WT and Col11a1deficient mice (Table 4).
Table 4:
Densitometric indices for the humeri (mean±SD) WT and Col11a1-/-.
Trabecular bone volume fraction (BV/TV) was calculated from Bone Volume (BV) and
Trabecular Volume (TV) values. Skyscan CT Analyzer was used to determine trabecular
thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp).
Statistical differences are reported as p values unless determined to be not significant
(ns). Control mice (n = 6), Col11a1-deficient mice (n = 3).

Genotype

BV/TV (%)

WT

25.3 + 2.9

Col11a1 -/-

43.7 + 4.1

% difference

72.7
p < 0.05

DA

Tb.Th (µm)

Tb.N
(1/mm)

Tb.Sp
(µm)

0.90 +
0.025
0.84 +
0.082
0.1
ns

18.32 +
0.22

13.8 + 1.5

33.2 + 1.81

35.3 + 3.7

12.4 + 0.81

91.6
p < 0.05

10.2
ns

38.9 +
1.19
17.2
p < 0.05

BMP-2 Induces the Expression of Col11a1 During Osteoblast Differentiation in a
SMAD-Dependent Manner
It has been shown that BMP-2 regulates periosteal bone formation during
development and we have previously shown that Col11a1 plays a role in BMP-2mediated alkaline phosphatase (ALP) expression [30, 56]. To evaluate a potential role for
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BMP-2 in the regulation of Col11a1 during osteoblast differentiation, we used the
pluripotent mesenchymal C2C12 cell line. When treated with BMP-2, C2C12 cells
changed their morphology from spindle to cuboidal-shaped cells (Figure 4A and 4B). To
confirm that BMP-2 induced osteoblast differentiation under our culture conditions, we
assessed the expression of well-established osteoblast markers alkaline phosphatase
(ALP), osteocalcin (OCN), runt-related transcription factor 2 (Runx2), and collagen I
alpha 1 (Col1a1). Our results showed an initial increase in early osteoblast differentiation
marker ALP up to day 2 that was followed by a decrease (Figure 4C). Similarly, Runx2
and Col1a1 expression increased up to day 3 followed by a decrease on day 6, while late
osteoblast marker OCN levels persistently increased reaching maximum expression on
day 6 (Figures 4D, 4E, and 4F). Further, BMP-2 induced the expression of Col5a1 in a
time-dependent manner during osteoblast differentiation (Figure 4G).
To determine if BMP-2 induces Col11a1 expression in C2C12 cells during
osteoblast differentiation, we treated cells with BMP-2 over a time course of 6 days. We
analyzed expression levels of Col11a1 as well as alternative exon expression on days 1,
2, 3, and 6 by quantitative real-time PCR. Our results demonstrate an induction of
Col11a1 expression by BMP-2 (Figure 3H) and an early and persistent increase in exon
6A up to day 6 (Figure 5A). The expression of exons 7 and 8 increased up to 2-3 days
and then decreased or plateaued (Figures 5C and 5D). Exon 6B expression was relatively
low compared to other exons and only showed a slight increase on day 3 (Figure 5B).
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Figure 4.
BMP-2 induces osteoblast differentiation in pluripotent C2C12 cells.
A) On day 6, C2C12 had changed morphology from mesenchymal spindle-shaped cells
to osteoblastic cuboidal shaped cells. B-F) On day 2, the expression of ALP, Runx2, and
Col1a1 was markedly increased in BMP-2-treated samples compared to control. ALP
mRNA levels decreased after day 2 and Runx2 and Col1a1 levels dropped after day 3.
However, OCN mRNA levels increased persistently up to day 6. G-H) The expression of
minor collagens V and XI also increased during osteoblast differentiation.
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Figure 5.
BMP-2 regulates Col11a1 mRNA levels in a time-dependent manner.
Total RNA was isolated from pluripotent mesenchymal C2C12 cells treated with BMP-2
(300 ng/mL) for the indicated number of days. Relative expression is reported as 2-ΔCT.
All samples were normalized to housekeeping gene peptidylprolyl isomerase A (PPIA).
A-D) Upregulated expression of exons 6A peaked on day 3 and remained increased up to
day 6; whereas, exons 7 and 8 mRNA levels peaked on day 2 and remained upregulated
until day 6. In contrast, BMP-2 induced a spike in exon 6B expression on day 3 that was
followed by a drop that was comparable to control cells. D) Expression of Col11a1
spliceform containing exons 6A- 7-8 was reduced. Statistical significance was calculated
using one-way ANOVA with Bonferroni’s Multiple Comparison post hoc test. Results
represent mean±SEM n = 3 in each group. * indicates p < 0.05, ** indicates p < 0.01, ***
indicates p < 0.001, and **** indicates p < 0.0001, and n.s. is not significant.
To elucidate whether induction of Col11a1 gene expression by BMP-2 was
dependent upon the canonical SMAD signaling pathway, we knocked down SMAD4 in
C2C12 cells using SMAD4 siRNA and lipofectamine (Figure 6A). SMAD4 knockdown
diminished BMP-2 induced Col11a1 gene expression (Figure 6B) demonstrating that
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regulation of Col11a1 expression by BMP-2 is dependent on the canonical SMAD1/5/8
signaling pathway.

Figure 6.
BMP-2 acts in a SMAD4-dependent mechanism to regulate collagen
XI alpha 1 expression in C2C12 cells. A) SMAD4 was knocked down using siRNA and
B) the expression of collagen XI alpha 1 was assessed using semi-quantitative PCR.
C2C12 cells pre-incubated in SMAD4 siRNA showed a reduced BMP-2-mediated
regulation of collagen XI alpha 1 expression.
PTHrP Modulates BMP-2-Induced Changes in Col11a1 Expression
Previous studies confirmed an inhibitory role for PTHrP (1-36) on BMP-2induced osteoblast marker expression [37] and thus we sought to investigate the effects of
PTHrP on BMP-2-induced Col11a1 expression. Quantitative real-time PCR demonstrated
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that PTHrP attenuated the BMP-2-induced splicing to include exon 6A and 8, and to a
lesser extent for exon 7 (Figures 7A and 7B). Combinations of alternatively spliced
exons included four predominant spliceforms; variable region exons 1) e6a-7-8, 2) e6b-7,
3) e8, and 4) e7, expressed by differentiating osteoblasts (Figure 7). PTHrP alone did not
have significant effects on Col11a1 expression at 24h continuous treatment.

Figure 7.
PTHrP alters BMP-2-induced expression of Col11a1 alternative
exons. Pluripotent mesenchymal C2C12 cells were treated with BMP-2 (300 ng/mL) for
five days and PTHrP (10-7 M) was added to select samples for 24 hr. As control, cells
were incubated in the absence of growth factors or presence of PTHrP only. Col11a1
exon expression was assessed by semiquantitative and quantitative real-time PCR using
different sets of primers. Relative expression is reported as 2-ΔCT. All samples were
normalized to housekeeping gene peptidylprolyl isomerase A (PPIA). A) and B) PTHrP
alone did not induce any significant changes in Col11a1 exon expression. In contrast,
combined with BMP-2, PTHrP reduced BMP-2-stimulated expression of exons 6A and 7.
Further, PTHrP was able to synergistically increase exon 6B expression with BMP-2,
although this effect was statistically not significant. Statistical significance was calculated
using two-way ANOVA with Bonferroni’s Multiple Comparison post hoc test. Results
represent mean±SEM n = 3 in each group. * indicates p < 0.05, ** indicates p < 0.01, ***
indicates p < 0.001, and **** indicates p < 0.0001.
Col11a1 Is Required for BMP-2 Induction of Osteoblast Markers During the First 24
Hours
To further elucidate the biological relevance of Col11a1 regulation by BMP-2
during osteoblast differentiation, we assessed the effects of Col11a1 knockdown on
BMP-2-induced expression of osteoblast markers ALP, OCN, Runx2, and Col1a1. Upon
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transfecting C2C12 cells with either Col11a1 siRNA or control scramble siRNA, we
confirmed our knockdown by RT-PCR (Figure 8A). We then determined the expression
levels of osteoblast markers using quantitative real-time PCR. Our results demonstrated
that Col11a1 knockdown caused a decrease in 24 hr BMP-2-stimulated osteoblast marker
expression, most markedly for ALP (Figures 8C-F). In contrast, this effect was reversed
later at 72 hr osteoblast differentiation (discussed below).

Figure 8.
Effects of Col11a1 KD on the expression of ALP, OCN, Runx2, and
Col1a1 is time-dependent. Pluripotent C2C12 cells were transfected with either Col11a1
or scramble siRNA for 24 hr. Next, cells were stimulated with BMP-2 (300 ng/mL) for
24 hr and 72hr. Relative expression is reported as 2-ΔCT. All samples were normalized
to housekeeping gene peptidylprolyl isomerase A (PPIA). A) At 24 hr BMP-2
stimulation, ALP expression was significantly decreased in Col11a1 deficient cells as
compared to control. In contrast, at 72 hr BMP-2 stimulation, Col11a1 deficient cells
showed a marked increase in ALP expression as compared to control. B) OCN mRNA
levels were not significantly different in Col11a1 deficient cells as compared to control at
24 hr BMP-2 treatment. By 72 hr, however, Col11a1-deficient cells expressed lower
levels of OCN as compared to control. C) and D) Both Runx2 and Col1a1 mRNA levels
were not significantly affected by Col11a1 KD at 24 hr BMP-2 stimulation; however, at
72 hr, both Runx2 and Col1a1 mRNA levels were significantly higher in Col11a1
deficient cells as compared to control. Statistical significance was calculated using twoway ANOVA with Bonferroni’s Multiple Comparison post hoc test. Results are reported
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as the mean±SEM n = 3 in each group. * indicates p < 0.05, ** indicates p < 0.01, ***
indicates p < 0.001, and **** indicates p < 0.0001, and n.s. is not significant.
Col11a1 siRNA Reduced BMP Activity in C2C12 Cells During the First 24 Hours
Because we found that Col11a1 was required for BMP-2 induction of osteoblast
markers during the first 24 hours, we tested the effects of Col11a1 on BMP signaling,
using a luciferase BMP-response element reporter construct. Treatment of C2C12 cells
with BMP-2 induced an increase in luciferase activity, indicating activation of BMP
signaling compared to untreated control cells (Figure 9). Col11a1 siRNA reduced the
BMP activity by 82% (p-value 0.0161) compared to controls in C2C12 cells during the
first 24 hours.

Figure 9.
Col11a1 recombinant p6B but not p7 reduces BMP-dependent
luciferase activation in C2C12 cells. C2C12 cells were transfected with a BMPresponsive firefly luciferase reporter plasmid and a control pCMV-β-gal reporter plasmid
for 24 hr. The next day, BMP-2 (300 ng/mL) and/or recombinant Col11a1 p6B (37.5
ug/mL) and p7 (62.5 ug/mL) were added to cultures and incubated for another 24 hr. Cell
lysates were analyzed for luciferase activity. Relative luciferase activity was calculated as
the ratio of luciferase to β-galactosidase activity, to control for transfection efficiency,
and is expressed as a multiple of the activity of unstimulated cells transfected with
reporter alone (control). Col11a1 p6B significantly reduced BMP-2-induced relative
luciferase activity. Similarly, Col11a1 KD diminished BMP-2-induced luciferase activity.
In contrast, Col11a1 p7 did neither enhance nor reduce BMP-2-induced luciferase
activity. Statistical significance was calculated using student’s paired t-test. Results
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represent mean±SEM n = 3 in each group. * indicates p < 0.05, ** indicates p < 0.01, ***
indicates p < 0.001, and **** indicates p < 0.0001, and n.s. is not significant.
Col11a1 Is Required for BMP-2-Induced Smad1/5/8 Phosphorylation
To elucidate the mechanism by which Col11a1 regulates BMP-2-induced
expression of osteoblast markers, we investigated the role of Col11a1 in SMAD1/5/8
phosphorylation and nuclear translocation in C2C12 cells by western blot and
immunocytochemistry. Treatment with BMP-2 induced SMAD1/5/8 phosphorylation,
which was not detected in control cells (Figures 10A-F). Further, phospho-SMAD1/5/8
co-localized with DAPI, indicating its presence in the nucleus (Figure 10F). Pretreatment with Col11a1 siRNA for 24 hours resulted in a reduction of phosphoSMAD1/5/8 by approximately 50% (p-value <0.001) (Figure 11A and 11B) and
inhibited the SMAD1/5/8 complex translocation to the nucleus (Figure 11G-I).
Interestingly, a 45% (p-value <0.01) increase in SMAD1 protein was observed in the
Col11a1-deficient cells compared to cells treated with the control scramble siRNA
(Figure 11B).
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Figure 10.
Col11a1 knockdown negatively affects canonical BMP-2 signaling.
C2C12 cells were plated on glass coverslips at 2 x 104 cells/cm2 and incubated overnight.
Next, cells were transfected with either Col11a1 or scramble siRNA for 24 hr and then
stimulated with BMP-2 for 30 minutes. Antibodies against Smad1 and PhosphoSmad1/5/8 were used to assess the effects of Col11a1 knockdown on BMP-2 mediated
Smad1/5/8 phosphorylation. A-I) Immunofluorescence staining was performed to look at
the effects of Col11a1 knockdown on Phospho-Smad 1/5/8 localization. No PhosphoSmad1/5/8 was detected in the nuclei of Col11a1 deficient cells as compared to control.
Instead, Col11a1 deficient cells showed a distinct punctuate pattern of staining
characterized by discrete “spots” close but not inside the nuclei.
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Figure 11.
Col11a1 knockdown negatively affects SMAD1/5/8 phosphorylation.
C2C12 cells were plated at 2 x 104 cells/cm2 and incubated overnight. Next, cells were
transfected with either Col11a1 or scramble siRNA for 24 hr and then stimulated with
BMP-2 for 30 minutes. Antibodies against Smad1 and Phospho-Smad1/5/8 were used to
assess the effects of Col11a1 knockdown on BMP-2 mediated Smad1/5/8
phosphorylation. Western blot analyses of C2C12 cells transfected with Col11a1 siRNA
or scramble siRNA was performed to quantify Smad1 and Phospho-Smad1/5/8 levels.
Col11a1 deficient cells showed a 40% decrease in Phospho-Smad1/5/8 levels as
compared to control. In contrast, Smad1 levels were 27% higher in Col11a1 deficient
cells as compared to control.
Recombinant Col11a1p8 NTD Fragment Enhances BMP-2-Induction of Osteoblast
Markers at 24 Hours
An essential role for Col11a1 during the first 24 hr of BMP-2 treatment was
further demonstrated by treating cells with recombinant Col11a1p8 NTD fragment,

34
representing one of the spliceforms synthesize by C2C12 cells as shown above. This
treatment resulted in an increase in OCN (19.5 fold, p-value 0.0103), Runx2 (3.0 fold, pvalue 0.0099), and Col1a1 (3.1 fold, p-value 0.0284) (Figures 12B-D). In contrast,
treatment with recombinant Col11a1p8 resulted in a 6.3 fold decrease (p-value 0.0143) in
ALP expression (Figure 12A).

Figure 12.
BMP-2-induced expression of ALP, OCN, Runx2, and Col1a1 is
altered by variable Col11a1 fragments. A) BMP-2 upregulated ALP expression was
significantly reduced upon incubation with Col11a1 p6B and p8. B) and C) OCN and
Runx2 mRNA levels were markedly increased when Col11a1 p6B and p8 were added to
BMP-2 treated cells as compared to control. D) Col1a1 expression was enhanced by
addition of Col11a1 p8 but reduced by Col1a1 p6B. Statistical significance was
calculated using student’s paired t-test. Results represent mean±SEM n = 3 in each group.
* indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p
< 0.0001, and n.s. is not significant.
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Col11a1 Inhibits BMP-2 Induction at Later Time Points During Osteoblast
Differentiation
In contrast to our observations after 24 hr BMP-2 treatment, the effect of Col11a1
siRNA was reversed later in osteoblast differentiation. After 72 hours of BMP-2
treatment, Col11a1 siRNA increased the expression of ALP, Runx2, and Col1a1 genes by
1.8 fold (p-value <0.01), 2.2 fold (p-value <0.01), and 5.6 fold (p-value <0.001),
respectively compared to scramble siRNA (Figures 8C, 8D, and 8F). Interestingly, OCN
expression level remained suppressed in the presence of Col11a1 siRNA compared to
scramble siRNA at 72 hr, similar to the effect seen at 24 hours (Figure 8E). This may
reflect the fact that osteocalcin is considered a late osteoblast differentiation marker.
Chondrocyte-Specific Isoform Col11a1p6b Inhibits BMP Activity in C2C12 Cells
To investigate the potential role of neighboring cartilage tissue on the formation
of the bone collar, we introduced a fragment from the isoform of Col11a1 that is
expressed by chondrocytes at the boundary between cartilage and the developing bone
collar on BMP signaling in osteoblasts, using the luciferase BMP-response element
reporter construct. Recombinant Col11a1p6b NTD fragment reduced the BMP activity by
64% (p-value 0.0136) while treatment of C2C12 cells with BMP-2 induced an increase in
luciferase activity compared to untreated control cells (Figure 9). Conversely, this effect
was not observed when cells were treated with a recombinant Col11a1p7 NTD fragment
that differs only by the absence of 51 amino acids encoded by exon 6b, indicating a
specific function for this 51 amino acid region in the regulation of growth plate
maturation, specifically bone collar formation.
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Chondrocyte-Specific Isoform Col11a1p6b Inhibits Expression of Osteoblast
Differentiation Markers in C2C12 Cells
To further test the role of Col11a1 as an osteoblast differentiation regulator, we
first treated C2C12 cells with BMP-2 and then cultured them in medium containing
recombinant Col11a16b NTD fragment to assess the expression of the markers of
osteoblast differentiation. Recombinant Col11a16b decreased the BMP-2-induced ALP
expression by 5.5 fold (p-value 0.0132) and Col1a1 expression by 1.8 fold (p-value
0.032) consistent with an inhibitory role for early marker expression (Figures 12A and
12D). Conversely, recombinant Col11a1p6B promoted the expression of OCN by 1.8
fold (p-value 0.017) and Runx2 by 3.4 fold (p-value 0.022) in BMP-2-induced cells
consistent with a positive regulatory role for later osteoblast differentiation (Figures 12B
and 12C).
Col11a1 Regulates C2C12 Proliferation in a Spliceform–Dependent Manner
Cellular proliferation of cells giving rise to the bone collar is an essential aspect of
bone development and is stimulated by BMP-2 in C2C12 cells. Proliferation and
differentiation events are highly coordinated in biological systems and thus we wanted to
look at the effects of Col11a1 on cellular proliferation in our model system. We found
that recombinant Col11a1p7 NTD fragment significantly increased the rate and extent of
proliferation of C2C12 cells treated with BMP-2. Two other spliceforms tested had only
minimal effects (Figure 13). Col11a1p7 was shown to be expressed at low levels in
C2C12 cells (see Figure 4C above), and increasing the level by the addition of
exogenous protein may have revealed a unique function for the smallest of the
spliceforms of Col11a1, Col11a1p7.
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Figure 13.
Col11a1 regulates cell proliferation during osteoblast differentiation.
C2C12 cells were cultured overnight in 96-well plates and recombinant Col11a1 protein
fragments p6B (37.5 ug/mL), p7 (62.5 ug/mL), and p8 (30 ug/mL) were added the next
day for 24 hr, 48 hr, and 72 hr. At each time point, 10 ul of wst-1 was added to each well
and incubated for 2 hr at 37ºC. Absorbance is reported as test wavelength of 450 nm
minus a reference wavelength of 630 nm. WST-1 was also added to empty and untreated
wells to establish a blank baseline. A) Addition of Col11a1 p6B to BMP-2 treated cells
did not significantly change cell proliferation at 24 hr and 72hr as compared to control
cells. However, at 48 hr, Col11a1 p6B enhanced cell proliferation as compared to both
untreated and BMP-2 only treated cells. B) Col11a1 p7 significantly enhanced cell
proliferation in C2C12 cells during osteoblast differentiation at all three time points. C)
Col11a1 p8 did not affect BMP-2 mediated cell proliferation at 24 hr and 72 hr but
significantly decreased cell proliferation at 48 hr time point. Statistical significance was
calculated using two-way ANOVA with Bonferroni’s Multiple Comparison post hoc test.
Results are reported as the mean±SEM n = 3 in each group. * indicates p < 0.05, **
indicates p < 0.01, *** indicates p <0.001, and **** indicates p < 0.0001, and n.s. is not
significant.
Discussion
Taken together, these findings suggest that Col11a1 spliceforms play specific
roles in the regulation of C2C12 osteoblast differentiation and that the effects of

38
individual spliceforms may be in opposition with respect to the other spliceforms.
Taking into consideration the results presented for the functional knockout mouse, these
findings are likely to translate to in vivo osteoblast differentiation and bone development.
Col11a1 is an extracellular matrix protein that is essential for proper skeletal
development. Marshall and Stickler syndrome patients carry heterozygous mutations in
Col11a1 and suffer from short stature and skeletal abnormalities. Previous groups have
shown that Col11a1-deficient mice exhibit increased skeletal mineralization compared to
their wildtype littermates [9, 11]. Based on recent microarray studies showing increased
Col11a1 presence during differentiation, we hypothesized that Col11a1 would affect
periosteal bone architecture and further alter osteoblast differentiation in a BMPdependent manner.
Our findings support a role for Col11a1 in bone formation consistent with
alterations to the bone collar during skeletal development. Further, we have presented
information that suggests intersection between BMP-2 signaling and Col11a1-regulation
of bone formation. Our results indicate that BMP-2 regulates Col11a1 transcription and
alternative splicing of pre-mRNA characterized by the expression of exons 6A, 7, and 8
in osteoblasts. BMP-2-stimulated expression of exon 6B on day 3 coincided with a
significant decrease in the expression levels of osteoblast markers ALP, Runx2, and
Col1a1, suggesting a negative regulatory role for exon 6B during osteoblast
differentiation. We also showed that exogenous treatment of cells with Col11a1[p6b-7]
recombinant protein fragment significantly reduced BMP activity . One possible
explanation for less BMP activity upon exposure to Col11a1[p6B-7] is its direct binding
to heparan sulfates on the surface of osteoblasts, which are responsible for trapping and
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internalizing BMP-2 into the cell [15 ,28, 29]. Our laboratory has previously shown that
Col11a1 binds specifically to heparan sulfate and heparan sulfate proteoglycans via the
p6b region and Npp domain [30].
Treatment of C2C12 cells with Col11a1[p6B-7] resulted in a significant decrease
in ALP and Col1a1 expression but not OCN and Runx2. Instead Col11a1[p6B-7] induced
increased expression of OCN and Runx2. This finding is intriguing because although
OCN is up-regulated by BMP-2 and is essential for osteoblast differentiation, OCNdeficient mice exhibit increased bone formation, suggesting a limiting role for OCN in
bone formation [31]. Furthermore, previous studies have shown that osteocalcin is under
direct regulation of Runx2 in osteoblasts [32]. Thus, it is possible that Col11a1p6b acts
upstream of Runx2 and induces the expression of Runx2 and OCN to limit bone
formation. Alternatively, since Runx2 is a shared target of BMP and TGF-β signaling
pathways [33], Col11a1[p6B-7]-mediated inhibition of BMP signaling at the receptor
level may signal the cells to increase TGF-β-induced expression of Runx2 and
subsequently OCN. Since BMP-2 increased the expression of exon 8, we postulated a
positive regulatory role for regions of the protein encoded by exons 6A, 7, and 8 during
osteoblast differentiation. Indeed, when we treated BMP-2-stimulated cells with
Col11a1p8, mRNA levels of OCN, Runx2, and Col1a1 increased significantly.
Surprisingly though, ALP expression was decreased by Col11a1p8.
Upon knocking down Col11a1, we initially observed a decrease in the expression
of osteoblast markers, suggesting that Col11a1 is required for BMP-2 mediated induction
of osteoblast marker expression. However, by 72 hr, we noted the opposite trend and
detected higher levels of osteoblast marker expression (except for OCN) in Col11a1-
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deficient cells as compared to control. This difference in the trend may be due to 1)
compensatory mechanism used by cells to increase their expression of osteoblast markers
and overcome the Col11a1 knockdown and/or 2) early induction of other genes that have
yet to be identified, perhaps other BMPs or receptors.
Continuous treatment with PTHrP has been shown to inhibit osteoblast
differentiation [25]. Previous teams have shown a feedback mechanism between BMP-2
and PTHrP during osteoblast differentiation, in which PTHrP attenuates BMP-2-induced
increases in osteoblast markers Runx2 and osterix [24]. Our findings indicate a regulatory
role for PTHrP in BMP-2-induced alternative splicing further supporting our postulation
of exons 6A, 7, and 8 as positive regulators of BMP-2 mediated osteoblast differentiation.
We also reported an increase in Col11a1 exon 6B expression when PTHrP was added to
BMP-2 treated cells although this effect did not reach statistical significance.
Canonical BMP signaling requires phosphorylation of SMAD1/5/8 and thus we
wanted to test whether Col11a1 knockdown affects this process. Our results clearly show
that Col11a1-deficient cells exhibit lower levels of phospho-SMAD1/5/8 as compared to
control cells. Furthermore, phospho-SMAD1/5/8 proteins in Col11a1-deficient cells are
primarily localized to the cytoplasm and not localized to the nucleus.
Considering the opposing relationship between cellular proliferation and
differentiation, we wanted to determine the effect of Col11a1 on BMP-2 mediated
regulation of cellular proliferation during osteoblast differentiation. Cellular proliferation
plays an important role in growth of long bone at the growth plate and bone collar. Our
findings demonstrate a proliferative role for Col11a1p6b and p7 when combined with
BMP-2 as compared to BMP-2 only treated cells. Conversely, Col11a1 p8 acts in an anti-
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proliferative manner, reducing BMP-2 mediated cellular proliferation. It is possible that
while Col11a1p6B acts as an inhibitor of osteoblast differentiation, it promotes cellular
proliferation instead. Conversely, Col11a1p8 might inhibit cell proliferation in favor of
cellular differentiation. Future studies on cell cycle analyses may answer questions about
the role of Col11a1 in cell proliferation.
In conclusion, our study clearly demonstrates a novel function for Col11a1 as a
regulator of BMP-2 induced osteoblast signaling and osteoblast differentiation. These
findings are consistent with our earlier studies suggesting that Col11a1p6b acts to inhibit
ALP expression during osteoblast differentiation [26]. Based on our observations, we
propose a model in which BMP-2 regulates Col11a1 in a spliceform-specific manner and
in return different spliceforms of Col11a1 act to either inhibit or enhance BMP-2
signaling and downstream expression of osteoblast markers correlated with the spatial
and temporal expression patterns within the developing long bone.
Future studies will address the role of Col11a1 in cell proliferation, direct binding
interactions between different collagen spliceforms and BMP-2, and the effects of
Col11a1 on integrin-mediated BMP-2 induction of osteoblast differentiation [34]. These
additional studies will offer more insight as to how Col11a1 plays a role in bone
development.
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CHAPTER TWO: A ROLE FOR PTHrP in ColXI (α1) ISOFORM EXPRESSION
DURING ATDC5 CHONDROGENIC DIFFERENTIATION
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Abstract
Alternative splicing is essential for protein diversity in eukaryotes. Long bones
develop as prechondrocytes differentiate and mature into hypertrophic chondrocytes,
which are eventually replaced by osteoblasts. Cellular differentiation and maturation
during chondrogenesis is tightly linked with pre-mRNA alternative splicing of important
extracellular matrix molecules including collages II and XI. ColXI (α1) splicing results in
up to eight different isoforms that are expressed in a spatiotemporal manner during
chondrogenesis. Here, we studied ColXI (α1) splicing during chondrogenesis using
mouse ATDC5 cells and pluripotent C2C12 cells. We also determined the effects of
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PTHrP on alternative ColXI (α1) transcript levels during chondrogenesis. Our results
showed that the expression of ColXI (α1) exons 6A and 8 did not change significantly
during the initial stages of chondrogenesis but reached peak levels on day 16. Further,
while exons 7 and 8 plateaued after day 16, exon 6A expression decreased. In contrast
ColXI (α1) exon 6B expression levels remained unchanged until day 30 of
differentiation. PTHrP had inductive effects on exon 6A and 8 expression levels during
early chondrogenesis but did not change exon 6B expression until day 30. Overall, this
study shows for the first time that PTHrP regulates ColXI (α1) alternative splicing during
chondrogenesis.
Keywords: ColXI (α1); alternative
chondrogenesis; differentiation.
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1. Introduction
The skeleton starts forming during the second month of human development.
Initially, mesenchymal cells condense and define the position and basic shape of the
future skeletal element. Once the initial mesenchyme condensations are formed,
depending on the growth factors present in the immediate environment, cells either
differentiate into osteoblasts to form bone or into chondrocytes to form cartilage [1]. Wnt
signaling drives mesenchymal cells to differentiate into osteoblasts [2]. In the absence of
Wnt signaling, SRY (Sex Determining Region Y)-Box 9 (Sox9) levels increase and
mesenchymal cells differentiate into prechondrogenic cells. Once committed,
prechondrogenic cells start producing cartilage extracellular matrix proteins including
collagens II and XI. Sox9 binds directly to the promoter of Col2a1 gene and induces its
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expression [3]. Although studies have shown Sox9 binding sites on collagen XI promoter,
Sox9-induced expression of collagen XI has not been reported [4]. Once prechondrocytes
are formed, cartilage starts growing rapidly in an appositional as well as interstitial
manner, a process known as endochondral ossification (Figure 1). Interstitial growth
occurs as prechondrocytes differentiate into chondrocytes, which then enlarge and
apoptose [5]. As chondrocytes hypertrophy, the perichondrium is infiltrated with blood
vessels induced by Vascular endothelial growth factor (VEGF) and the periosteum is
formed [6]. The periosteum houses mesenchymal cells that upon getting a signal from
hypertrophic cells differentiate into osteoblasts. Bone is formed as osteoblasts start
producing a non-mineralizing fibrillar extracellular matrix, which is then organized into
mineralized matrix. Proper bone growth is dependent upon a complex network of
systemic and local growth factors.
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Figure 1.
Long bones elongate as resting chondrocytes undergo differentiation
into proliferative chondrocytes. PTHrP produced by perichondrial and resting
chondrocytes maintains cells in a proliferative state. Proliferative chondrocytes then
hypertrophy and undergo apoptose as cells of the bony collar become osteoblasts. BMP-2
is an inducer of chondrocyte hypertrophy, whereas IHH produced by pre-hypertrophic
chondrocytes signals to synthesize more PTHrP and thus inhibit hypertrophy.
Initially Sox9 is essential for commitment into cartilage. Prechondrocytes and
cells of the perichondrium both synthesize Parathyroid hormone-related Peptide (PTHrP)
to maintain chondrocytes in a proliferative state [7]. Prehypertrophic cells on the other
hand produce Indian Hedgehog (IHH), which promotes hypertrophy [8]. Simultaneously,
cells of the periosteum respond to growth factors released by hypertrophic chondrocytes
and promote differentiation of mesenchymal cells into osteoblasts. Bone morphogenetic
protein-2 (BMP-2) is crucial for promoting chondrocyte hypertrophy as well as osteoblast
differentiation in the growth plate [9]. Interstitial and appositional growth processes are
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linked and the accurate orchestration of different mediators is crucial in achieving proper
bone growth.
Fibrillar collagens are abundant extracellular matrix proteins that provide
structure and support for cells [10, 11]. During endochondral ossification, collagens are
expressed in a spatiotemporal manner [12]. The major fibrillar collagen present in
cartilage is collagen type II, whereas collagen type I is predominantly found in bone.
Collagens V and XI are minor in abundance relative to collagens I and II; however, their
presence is required for proper fibril formation [13]. Collagens are formed as procollagen
chains and three alpha chains come together to form a heter- or homo-trimer protein in
the extracellular matrix. Previous studies have shown that collagen V is often associated
with collagen type I, whereas collagen XI is associated with collagen type II in cartilage.
Collagen XI is an important component of the collagen network in cartilage and is
essential for growth plate development [14, 15]. Interestingly, exons within the variable
region of the amino terminal domain of all three collagen XI alpha chains are
alternatively spliced [16]. This is intriguing because the globular amino-terminal domain
of collagen XI containing the variable region is not completely embedded in the collagen
fibrils but instead projects away from the fibril surface [17]. Alternative splicing of
collagen XI alpha I chain involves exons 6A, 6B, 7, and 8 encoding the variable region
[18, 19] (Figure 2). Previous work has shown that there is a strong link between
chondrogenesis and ColXI (α1) alternative splicing in fetal rat limb buds [19]. Similarly,
there is compelling evidence that the different ColXI (α1) spliceforms are regulated in a
spatiotemporal manner during growth plate development [12].
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Mutations in Parathyroid hormone- 1- receptor (PTH1R) result in skeletal
dysplasias including Blomstrand’s chondrodysplasia and Jansen Metaphyseal
Chondrodysplasia characterized by short-limbed dwarfism due to abnormal growth plate
development [20–23]. Similarly, ColXI (α1) mutations exhibit short-limbed dwarfism
and improper growth plate development [24–26]. Based on the overlap in phenotype and
co-localization in the growth plate for ColXI (α1), PTHrP, and PTH1R, we hypothesized
that PTHrP regulates ColXI (α1) alternative splicing and expression in a differentiationspecific manner. We predicted that treatment with PTHrP would alter the pattern of
ColXI (α1) spliceform expression in chondrocytes and pluripotent cells. We tested our
hypothesis using commercially purchased PTHrP and prechondrogenic ATDC5 cells and
pluripotent C2C12 cells in culture. We first characterized the expression ColXI (α1)
alternative spliceforms during ATDC5 chondrogenesis and then assessed the effects of
PTHrP on the expression of ColXI (α1) alternative spliceforms in both ATDC5 and
pluripotent C2C12 cells.
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Figure 2.
The variable region within the NTD domain of collagen XI alpha 1
undergoes alternative splicing that can result in several different isoform. Each
spliceform is expressed in a distinct spatiotemporal manner during development. The
exact function of alternative splicing in collagen XI alpha 1 is yet to be determined
(Adapted from [19]).
Our results clearly demonstrate that PTHrP modulates ColXI (α1) alternative
splicing during ATDC5 chondrogenesis. In contrast, the expression of ColXI (α1) in
pluripotent C2C12 cells does not change with PTHrP treatment. Taken together, our
results suggest a regulatory role for PTHrP on ColXI (α1) expression during
chondrogenesis promoting the expression of exons 6A and 8 during early chondrogenesis
and exon 6B at later stages of chondrocyte differentiation. Our study provides insight into
the role of PTHrP on ColXI (α1) alternative splicing and may be important for future
studies on the interaction between the molecules.
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2. Results and Discussion
2.1. Characterization of Collagen XI Spliceform Expression During ATDC5
Chondrogenic Differentiation
To examine the expression pattern of different ColXI (α1) spliceforms during
chondrogenesis, we differentiated mouse ATDC5 cells in culture to recapitulate the
process of chondrogenesis in vitro. ATDC5 cells provide an outstanding model to study
processes of chondrogenic differentiation in vitro [27]. Cells stimulated with insulintransferrin-selenium (ITS) showed positive Alcian blue staining for proteoglycans
suggesting chondrogenesis (Figure 3a). We also confirmed chondrocyte differentiation
of ATDC5 cells on a gene level by assessing the expression of well-known chondrogenic
markers Col2a1 and PTH1R. Our results showed a 4-fold increase in Col2a1 expression
on day 10 (p-value <0.05) and an 11-fold increase on day 16 (p-value <0.0001).
Similarly, although at much higher levels, PTH1R expression increased reaching peak
levels on day 16. Both Col2a1 and PTH1R expression levels decreased after day 16 in
agreement with their roles as early differentiation markers [28] (Figure 3b).
To determine the extent of ColXI (α1) alternative splicing during chondrogenesis,
we designed primers specific to each alternatively spliced exon within the variable region
of ColXI (α1) (Table 1). Real-time PCR analysis demonstrated that ColXI (α1) exons
6A, 7, and 8 peaked at early to mid stages of chondrocyte differentiation (Figure 3c, 3e,
3f), whereas ColXI (α1) exon 6B was more prevalent during later stages of chondrogenic
differentiation (Figure 3d). These results are intriguing because previous work has
shown that peptides p6A and p8 encoded by exons 6A and 8 are predominantly found
during early stages of chondrocyte differentiation in rat long bones [12, 19] Similarly, our
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laboratory has previously shown that the predominant spliceform during early stages of
zebrafish development included exons 6A, 7, and 8 [29]. Conversely, ColXI (α1) peptide
p6B encoded by exon 6B is almost exclusively found at the periphery of cartilage
underlying the perichondrium preceding the bony collar. In addition, ColXI (α1) p6B
overlaps with collagen type X in fetal rat long bones suggesting a role for p6B in terminal
chondrocyte differentiation [12].
Table 1:
Program.

List of real-time primers designed using NCBI’s Primer Blast

GENE

SENSE PRIMER

ANTISENSE PRIMER

SIZE(bp)

COL2A1

ACGAAGCGGCTGGCAACCTCA

CCCTCGGCCCTCATCTCTACATCA

73

COL11A1 e6A

AGGCTGAGAGTGTAACAGAGA

TCTGTTTGTGCTACTGTTTCTTCA

58

COL11A1 e6B

GTTCACATCCCCCAAATCTGA

CCCCTAGTTTGGCTTTGGCT

80

COL11A1 e7

GGAACAATGGAACCTTACCAGAC

ATTCGATCCTGATACCCGCC

54

COL11A1 e8

AGGAGTAGACGGCAGGGATT

GGAGGTCGTAGTCCTTTCTTCA

100

PPIA

CGCGTCTCCTTCGAGCTGTTTG

TGTAAAGTCACCACCCTGGCACAT

150

PTH1R

GGGCACAAGAAGTGGATCAT

GGCCATGAAGACGGTGTAGT

210

56

Figure 3.
(a) Prechondrogenic ATDC5 cells were treated with differentiation
medium as described in experimental and incubated in culture for 30 days.
Chondrogenesis was monitored using Alcian Blue Stain. (b) The expression of PTH1R
and Col2a1 increased up to day 16 and then dropped up to day 30 in culture. (c) Collagen
XI alpha is alternatively spliced during ATDC5 chondrogenic differentiation. Exon 6A
and 8 expression levels peak on day 16 of chondrogenic differentiation, whereas exon 7
peaks on day 16 and remains increased. In contrast exon 6B expression reaches highest
level on day 30 of differentiation.
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2.2. A Role for PTHrP (1-36) in Collagen XI Alpha 1 Splice Form Expression in ATDC5
Chondrocytes
In differentiated chondrocytes, PTHrP (1-36) downregulated PTH1R expression
by 3.3-fold (p-value <0.05) on day 16 (Figure 4). PTHrP (1-36)- induced
downregulation of PTH1R was also observed on days 22 and 30, albeit at lower levels,
2.6-fold and 2.3-fold respectively. These results are interesting because other groups have
shown an antagonistic role for PTHrP on PTH1R expression in human mesenchymal
stem cells and mouse vascular smooth muscle cells [30, 31]. In addition, previous studies
have shown a complementary expression pattern for PTHrP and PTH1R in osteoblasts
[32]. In the growth plate, it is known that PTHrP secreted by perichondrial cells acts on
proliferating chondrocytes to limit their terminal differentiation into hypertrophy. PTH1R
on the other hand is widely expressed in pre-hypertrophic chondrocytes of the growth
plate and promotes hypertrophy [33]. It is thus possible that PTHrP downregulation of
PTH1R in our study reflects the effects of PTHrP on PTH1R expression in growth plate
chondrocytes during endochondral ossification.
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Figure 4.
ATDC5 cells were differentiated into chondrocytes over 30 days cells
were treated with PTHrP (10-7 M) for 24 hours on days 0, 3, 10, 16, 22, and 30. 2 ug
of total RNA was used to run real-time PCR and assess the expression of PTH1R as
a result of PTHrP treatment. Here, it is shown that PTHrP has no significant effects on
PTH1R expression at the early stages of chondrogenic differentiation. After 16 days in
incubation medium however, PTHrP reduces PTH1R expression levels by 3.3-fold
compared to untreated cells. PTHrP-induced decrease in PTH1R expression is sustained
throughout the chondrogenic differentiation stages reaching peak levels on day 16.
To determine whether PTHrP (1-36) modulates ColXI (α1) alternative splicing
and expression levels during chondrogenesis, we treated ATDC5 cells at different stages
of chondrocyte differentiation with PTHrP (1-36) for 24 hours and analyzed gene
expression using real-time PCR. PTHrP (1-36) increased the expression levels of ColXI
(α1) exons 6A and 8 by 2-fold (p-value <0.05) and 2.2-fold (p-value <0.05), respectively,
on day 3. At later stages, PTHrP (1-36) had the opposing effects on ColXI (α1) e6A
expression and decreased its expression by two-fold (p-value <0.05) on day 30. In
contrast, PTHrP (1-36) treatment did not significantly change ColXI (α1) e6B expression
during early stages of chondrogenesis but increased e6B expression by 3-fold (p-value
<0.05) and 2-fold (p-value <0.05) on days 22 and 30, respectively. These findings
support the concept of ColXI (α1) exons 6A and 8 as early chondrogenic markers that are
increased by PTHrP to maintain cells in a proliferative state. Similarly, it is possible that
PTHrP up-regulates ColXI (α1) exon 6B expression only at later stages of differentiation
at the bone collar to promote terminal differentiation.
2.3. Effects of PTHrP (1-36) on Collagen XI alpha 1 Expression in Pluripotent C2C12
Cells
To determine whether PTHrP (1-36) regulates ColXI (α1) expression in a
pluripotent stem cell model, we used mouse C2C12 cells, which can be used as a model
for cells found at the bone collar. C2C12 cells can differentiate into myoblasts,
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osteoblasts, adipocytes, and neurons. Here, we used C2C12 cells as a pluripotent stem
cell model and assessed ColXI (α1) expression upon PTHrP (1-36) treatment. Our results
showed no significant changes in ColXI (α1) alternative spliceform expression at any
time point treatment (Figures 6 a-d). To confirm our findings, we co-treated PTHrPtreated cells with a PKA inhibitor H89 and as expected did not observe any significant
changes to the expression levels (data not shown). It is important to note that we used
PTHrP in a continuous fashion to treat C2C12 cells. Previous studies have shown
opposing roles for PTHrP (1-36) depending on whether it was used in a continuous
PTHrP or intermittent manner. Continuous PTHrP (1-36) treatment results in bone loss,
whereas intermittent exposure can increase bone formation [34].
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Figure 5.
(a) ATDC5 cells were differentiated into chondrocytes and
chondrogenesis was assessed using Alcian Blue and Alizarin red. (b) PTHrP treatment of
ATDC5 cells increased ColXI (α1) exon 6A expression during early stages of
chondrogenesis but decreased its expression on day 30. (c) PTHrP increased ColXI (α1)
exon 6B expression during late stages of chondrogenesis. (d) PTHrP did not affect exon 7
expression during early chondrogenesis but increased its expression on days 16 and 22.
On day 30, PTHrP did not change ColXI (α1) exon 7 expression. (e) ColXI (α1) exon 8
expression is increased by PTHrP on day 3 similar to exon 6A but remains unchanged
with treatment at later stages of chondrogenesis.
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Figure 6.
(a-d) PTHrP did not affect the expression and alternative splicing of
ColXI (α1) in pluripotent C2C12 cells. Cells were plated at 2x104 cells/cm2 and grown
overnight in maintenance medium. The next day, cells were treated with PTHrP for 2 hr,
4 hr, 12 hr, and 24 hr continuously. RNA was extracted and the expression of ColXI (α1)
spliceforms was assessed using real-time PCR.
3. Experimental Section
3.1. Cell Culture, Differentiation, and Treatment
The mouse pluripotent cell line, C2C12 was purchased from ATCC and
maintained in DMEM (Sigma Chem. Co., St. Louis, MO) supplemented with 10% fetal
bovine serum (FBS) (GIBCO, Grand Island, NY) and antibiotics (100 units/mL of
Penicillin-G and 100 μg/mL of Streptomycin). Cells were kept at 37°C in a humidified
atmosphere of 5% CO2 in air. To assess PTHrP effects, cells were plated at 2 x 104
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cells/cm2 in DMEM supplemented with 10% FBS, 100 U/mL Penicillin and 100 μg/mL
Streptomycin and hPTHLH (10-7 M) (Sigma Aldrich; St. Louis, MO) for the indicated
amount of time. At each time point, total RNA was extracted from the cells using TriZol
(Gibco-BRL) and real-time PCR was performed as described below.
For chondrogenesis experiments, prechondrogenic cells mouse ATDC5 cells were
purchased from ATCC and maintained in DMEM: F12 (1:1) supplemented with 5% fetal
bovine serum (FBS) (GIBCO, Grand Island, NY) and antibiotics (100 units/mL of
Penicillin-G and 100 μg/mL of Streptomycin). For differentiation studies, ATDC5 cells
were grown in micromass cultures as following: cells were suspended at 1.0 x 107
cells/mL in maintenance medium supplement with ITS-G (Insulin-Transferrin-Selenium,
Life Technologies, Carlsbad, CA). Three 10 μl drops were placed into a well of a 6-well
plate and let adhere for 2 hr in the incubator. Two milliliters of media was added to each
well. Media was changed every two days. PTHrP was added on days 0, 3, 10, 16, 22, and
30. RNA was extracted using 1 mL TriZol per well of a 6-well plate.
3.2. Alcian Blue and Alizarin Red Staining
ATDC5 cells were plated in micromass cultures as described above in 12-well
plates and cultured in differentiation medium for 30 days. At each time point, cells were
rinsed with PBS and fixed with 95% methanol for 15 minutes. Then, cells were stained
with 0.1% Alcian Blue 8GS (Fluka, Buchs, Switzerland) in 0.1M HCl overnight at room
temperature. The next day, cells were rinsed with PBS and imaged using an Olympus
America’s BX53 microscope.
For mineralization, cells were cultured in differentiation medium on glass
coverslips as described above and incubated for 30 days. On day 30, cells were rinsed
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three times with PBS and fixed in 95% ethanol for 15 min. Cells were then stained with
400 μl of 40 mM Alizarin Red (Millipore, Billerica, MA) for 20 minutes. After
destaining with deionized water, samples were imaged using an AMG EVOS
Fluorescence Microscope.
3.3. Primer Design and Real-Time PCR
Primers were designed for each exon using Primer Blast (NCBI) (Table 1). Realtime PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems,
Life Technologies). Each 20 μL PCR reaction consisted of 10 μL of SYBR Green PCR
Master Mix, 500 nM of each forward and reverse primer, and 1 μL of undiluted template
cDNA and nuclease-free water. Targets were amplified using Eppendorf Mastercycler as
following: 50°C (2 min), 95°C (10 min) followed by 40 cycles of 95°C (15 sec) and 60°C
(1 min) followed by one cycle of 72°C (1 min). PCR products were separated by
electrophoresis through 4% Nusieve 3:1 Agarose as per manufacturer’s instructions
(Lonza, Basel, Switzerland) to verify that the used primer pair produced the expected
product. A no-template control was also included in the assay substituting water for
template.
3.4. Statistics
Results are reported as the mean±SEM n = 3 in each group. One-way ANOVA
followed by post-hoc Bonferroni test was used to determine the statistical differences
between the various experimental and control groups. * indicates p < 0.05, ** indicates p
< 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001, and n.s. is not significant.
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4. Conclusions
In summary, our findings indicate that collagen XI alpha 1 is alternatively spliced
during ATDC5 chondrogenic differentiation in vitro. These results will enable further
studies on the role of different collagen XI alpha 1 spliceforms during chondrogenesis. In
addition, our work provided evidence for a role for PTHrP in collagen XI alpha 1
alternative splicing and expression in ATDC5 cells. We also showed that continuous
PTHrP (1-36) did not alter ColXI (α1) spliceform expression in pluripotent C2C12 cells.
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ABSTRACT
An essential aspect of craniofacial development is chondrogenesis, the process of
chondrocyte differentiation from multipotent neural crest cells. These multipotent cells
delaminate from the neural tube during neurulation, travel along specific routes and
differentiate into various cell types forming different tissues. The formation of this wide
range of neural crest cell derivatives is dependent on multiple factors, including
transcription factors, extracellular matrix proteins, and growth factors. Sox proteins are
transcription factors that play a role during development of various tissues. L-Sox5,
Sox6, and Sox9 play a role in the differentiation of neural crest cells into chondrocytes by
binding to regulatory elements, enhancing the expression of chondrocyte-specific
collagens. Minor fibrillar collagens V and XI contribute to chondrogenesis of the
craniofacial skeleton by mechanisms that include the regulation of collagen
fibrillogenesis and a bridging function between major fibrillar collagens and other cell or
matrix molecules. However, the mechanism of regulation is not fully understood.
Disruption of craniofacial development during chondrogenesis can lead to Stickler
Syndrome or Campomelic Dysplasia as a result of collagen XI and Sox9 mutations,
respectively.
*Corresponding author: Dr. Julia Thom Oxford,
1910 University Dr., Department of Biological Sciences, Boise, ID 83725-1515, USA.
joxford@boisestate.edu

Here, we focus on potential additional mechanisms by which the extracellular matrix
plays a role in Sox-mediated chondrogenesis during craniofacial development. PTHrP
may be the link between the expression of extracellular matrix and Sox transcription
factor family-mediated regulation of chondrogenesis, creating a regulatory cycle that
supports growth and development of cartilage-derived structures.
KEYWORDS: Sox9, craniofacial, chondrogenesis, neural crest cells, collagen, PTHrP
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ABBREVIATIONS
Sox (Sry (Sex determining Region Y)- HMG box), ECM (Extracellular Matrix), EMT
(Epithelial-Mesenchymal Transition), FGF (Fibroblast Growth Factor), Hox
(Homeobox), NCC (Neural Crest Cell), CD (campomelic dysplasia), cyclic-AMP
(cAMP) response element-binding (CREB), BMP (Bone Morphogenetic Protein), MAP
(Mitogen-Activated Protein), PGC1-α (Proliferation activated receptor gamma coactivator 1- alpha), TRAP (thyroid hormone receptor associated protein), PKA (Protein
Kinase A), PNS (Peripheral Nervous System), PTHrP (Parathyroid hormone-related
protein).

INTRODUCTION
Congenital craniofacial abnormalities span a spectrum of deformities including cleft
palate, deformed jaw, severe defects of the eye, and mental retardation. Due to the nature
of these disorders, treatment is limited and can lead to lifelong physiological and
psychological suffering of the concerned individuals.
The craniofacial skeleton is formed via intramembranous and endochondral ossification
in which cartilage formation precedes that of bone. Multipotent mesenchymal cells
condense and differentiate into chondroblasts, which then proliferate rapidly and
differentiate into chondrocytes. Chondrocytes deposit the cartilage-specific extracellular
matrix (ECM) proteins, proliferate, and become hypertrophic. Upon hypertrophy, the
cells grow in size, alter their collagen expression, and eventually undergo apoptosis.
Simultaneously, mesenchymal cells surrounding the hypertrophic cartilage differentiate
into osteoblasts and secrete bone matrix, while osteoclasts degrade the hypertrophic
cartilage as the cartilage model is replaced with newly formed bone tissue [1].
Collagen is the most prevalent protein found in the ECM, with 29 different types
discovered to date [2, 3]. Based upon abundance, collagens are divided into major
fibrillar collagens, including collagen types I and II, and minor fibrillar collagens,
including types V and XI. Collagens V and XI can form hybrid molecules, therefore they
are considered to belong to the same collagen type, which can be referred to as collagen
type V/XI. In vivo studies of collagen V/XI morphants have demonstrated their role as
regulatory proteins that contribute to fibrillogenesis [4, 5]. However, while major fibrillar
collagens have been studied extensively, additional roles for minor fibrillar collagens in
cellular differentiation and signaling require further study and are still being defined.
The cartilaginous framework of the craniofacial skeleton is formed by differentiation of
multipotent neural crest cells (NCCs) into mature chondrocytes. Disruption of
chondrogenesis causes severe facial skeletal structure abnormalities and has detrimental
effects on the embryo. Deformities of the craniofacial features can be induced by genetic
factors. For instance, mutations in minor fibrillar collagens V/XI can cause Marshall,
Stickler, or Ehlers-Danlos syndromes, which all present complex phenotypes of flattened
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face, hearing loss, eye abnormalities, and joint problems. Likewise a mutation of the Sox9
gene in humans can result in campomelic dysplasia (CD) [6], a genetic condition
characterized by craniofacial defects, severe damage of the endochondral bone, and sex
reversal [7]. Similar anomalies are observed in vivo when Sox9 ortholog genes are
knocked out in other species including zebrafish (Danio rerio), mouse (Mus musculus),
and frog (Xenopus laevis). Interestingly, Parathyroid Hormone-related Protein (PTHrP)
homozygous mutant mice also exhibit a chondrodysplastic phenotype characterized by a
deformed skull, short snout and mandible, protruding tongue, and disproportionately
short limbs, which are all similar to characteristics in human osteochondrodysplasias [8].
In all the above-mentioned disorders, chondrogenesis and bone formation are interrupted
in the development of the craniofacial structures.
NCCs represent a population of multipotent stem cells that arise from the rhombomeres
of the hindbrain in vertebrates. These cells undergo an epithelial-mesenchymal transition
(EMT) during the first few weeks of embryogenesis and migrate to different sites in the
body, where they differentiate into neuronal cells, cardiac crest cells, pigment cells,
chondrocytes, and osteocytes [9, 10, 11]. Differentiation into this wide array of derivative
cells is tightly regulated by transcription and growth factors. The different transcription
and growth factors work together within a complex system and achieve proper formation
of the craniofacial skeleton and other developmental structures during embryogenesis.
Growth factors such as fibroblast growth factor (FGF), Wnt, bone morphogenetic protein
(BMP), PTHrP, and transcription factors including Hox and Sox proteins influence
chondrogenesis and thus the development of the craniofacial skeleton [12]. Within the
Sox (SRY- HMG box) transcription family, L-Sox5, Sox6, and Sox9 regulate
chondrogenesis [13] shown by L-Sox5sox6 double mutants, which lack endochondral
bones and exhibit severe skeletal abnormalities [14]. Similarly, PTHrP plays a role in
proper endochondral ossification as indicated by PTHrP-deficient mice exhibiting
abnormalities of the craniofacial cartilages and skeletal deformities [15].
Due to similar anomalies observed in PTHrP, Sox9, and minor fibrillar collagen mutant
model organisms, investigation into the potential link between the three factors may
provide fundamental knowledge regarding the mechanisms at play during chondrogenesis
of neural crest derivatives, a possibility that has not been characterized.
Craniofacial development and neural crest cells
Craniofacial cartilage structures can be divided into seven prominences including the
frontonasal, and one pair each of the mandibular, maxillary and lateral nasal (Figure 1)
[16]. The frontonasal features arise from NCCs to comprise the forehead, nose, upper lip,
and primary palate. Structures of the mandibular and maxillary prominences include the
lower jaw, sides of the face, and lips [16, 17].
Upon gastrulation, the ectoderm forms the non-neural ectoderm, the neural plate and the
NCCs [18]. Cells of the non-neural ectoderm form the epidermis, while the neural plate
folds to give rise to the central nervous system, including the brain and the spinal cord
[19]. During the initial stages, the brain is divided into three primary vesicles: the
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Figure A1. Neural crest cell migration from the posterior midbrain and
rhombomeres of the hindbrain to various sites of differentiation. NCCs from the
posterior midbrain migrate to the frontonasal region and contribute to nasal structures as
well as to the first pharyngeal arch forming Meckel’s cartilage. NCCs migrate from
rhombomeres 1, 2, and 3 form Meckel’s cartilage, whereas rhombomeres 4 and 5 make
up ear structures and part of the hyoid bone. NCCs from rhombomeres 5 and 6 form the
greater horn of the hyoid bone. Similarly, rhombomere 7 NCCs migrate to form thyroid
and cricoids cartilages. NCCs from rhombomere 8 give rise to tracheal cartilages.
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forebrain, midbrain and hindbrain. The hindbrain, or rhombencephalon, consists of
rhombomeres where NCCs originate. These mesenchymal cells migrate to the frontonasal
region and to one or more of the 6 pharyngeal arches (Figure 1). Each pharyngeal arch
gives rise to specific structures of the craniofacial and neck skeleton. Pharyngeal arch 1
forms the mandibular and maxillary structures including the maxilla, zygomatic bone,
temporal bone, incus, malleus, and Meckel’s cartilage. Pharyngeal arch 2 shapes the
stapes, styloid process, and hyoid bone. Pharyngeal arch 3 makes up the greater horn of
the hyoid bone, and pharyngeal arches 4-6 form the arytenoid cartilage, thyroid cartilage,
and other laryngeal cartilages [20].
Collagens V/XI are expressed in pre-migratory NCCs as well as in developed craniofacial
cartilages in zebrafish [21, 22]. Interestingly, the expression patterns of the minor fibrillar
collagens are highly comparable to that of Sox9 in the craniofacial structures, although
there is no direct evidence showing an interaction between Sox9 protein and minor
fibrillar collagen genes. Similarly, accelerated endochondral bone formation and
chondrocyte maturation in the craniofacial cartilaginous structures in PTHrP-deficient
mice indicate expression of PTHrP in the craniofacial structures [23].

Minor fibrillar collagens and SOX proteins
During endochondral ossification, chondrocytes deposit major collagen type II and minor
fibrillar collagen type V/XI [24]. As cartilage is mineralized and converted to bone,
chondrocytes change their overall expression pattern to collagen type I and more
predominantly minor fibrillar collagen V. Collagens consist of three peptide alpha chains
forming either heterotrimers or homotrimers [25, 26, 27]. Three different collagen XI
alpha chains have been described: Col11a1, Col11a2 and Col11a3 [28, 29]; where
Col11a3 is actually a modified form of Col2a1. Similarly, three collagen V alpha chains
have been described in humans: Col5a1, Col5a2 and Col5a3 [21]. Minor fibrillar
collagens V and XI play a role in the organization of major fibrillar collagens I and II,
respectively, by forming heterotrimers with them. Collagens V/XI share strong homology
among their respective protein domains and are interchangeable, forming collagen V/XI
isoforms [30, 31, 32].
What can we learn from animal models?
The role of collagen V/XI in chondrogenesis of craniofacial skeletal structures has been
studied in mice and in zebrafish [4, 5]. Expression of Col5a1 in developing cranial
cartilages, Col11a2 expression in cephalic mesoderm, and a unique Col11a1 expression
in the hindbrain has been identified in zebrafish [21], suggesting a potential role in the
induction and differentiation of NCCs into craniofacial cartilages. This potential is
supported by vertebral and craniofacial abnormalities in zebrafish Col11a1 morphants.
The abnormalities include a smaller lower jaw and abnormal otolith genesis (Figure 2A).
Analogous defects have been observed in chondrodysplasia (cho/cho) mice lacking a
functional Col11a1 protein (Figure 2B). The cho/cho mouse demonstrates a morphology
characteristic of Marshall’s and Stickler syndromes and fibrochondrogenesis in humans
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[33]. Likewise, mutations in Col11a2 have been linked to osteochondrodysplasias in
humans [34].

Figure A2. Effects of Col11a1 knockdown in mouse and zebrafish. Col11a1
morphant zebrafish show a smaller mandible (M) and smaller otoliths (arrowhead).
Similarly, microcomputed tomography representation of wildtype (WT) and Col11a1
mutant chondrodysplastic (cho) mice at embryonic day 17.5 show an overall smaller,
deformed cranium (dashed lines), and decreased jaw length (bar), illustrating the role for
Col11a1 in craniofacial development.
Multiple families of transcription factors are responsible for the expression of genes
necessary for chondrogenesis. One essential family of transcription factors is represented
by the highly conserved Sox family. All Sox proteins share the same high mobility
(HMG) domain that is extraordinarily conserved among vertebrates (Figure 3) and bind
to a similar minor groove DNA motif of (A/T)(A/T)CAA(A/T)G resulting in bending of
the DNA helix [7, 35, 36]. Bending of the DNA facilitates the unwinding of the DNA
double helix, which in turn causes the gene promoters to be in a more open conformation
and enhance transcriptional activity. Sox transcription factors are divided into 8
subgroups of A-H [37]. Sox9 is a transcription factor that belongs to subgroup E and has
a characteristic transcription domain at its C-terminus [38]. Sox9 is expressed in a variety
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of cell types, including mesenchymal NCCs, Sertoli cells of the testes, cardiac neural
crest cells, the kidney, and all chondroprogenitor cells [4]. Along with Sox9, other SoxE
members such as Sox8 and Sox10 play a role in the development of the NCCs prior to
their migration. Once the NCCs start migrating, Sox9 expression is downregulated and
expression of Sox8 and Sox10 are lost. However, upon arrival at the site of
chondrogenesis, the NCCs up-regulate Sox9 [16]. Sox9 does not play a role in NCC
migration as evidenced by normal cell migration patterns in Sox9 mutant cells [1].
Nonetheless, at the site of chondrogenesis, Sox9 plays a crucial role in not only
mesenchymal cell condensation, but also proliferation and differentiation into
chondrocytes [39, 7].

Figure A3. Schematic of a potential mechanism by which extracellular matrix
proteins can act upstream or downstream of PTHrP in the cell. Collagens V/XI may
act upstream and interact with PTHrP or PTHrP receptor in the extracellular matrix
activate the PKA pathway, and regulate chondrogenesis via Sox9. Alternatively, PTHrP
may regulate the expression of minor fibrillar collagens V/XI by activating the PKA
pathway and phosphorylating Sox9 in the cytoplasm, which can then move to the nucleus
and regulate the expression of the minor fibrillar collagens in a similar manner that it
regulates Col2a1. Both Col11a1 and Col11a2 have transcription sites for Sox9.
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Additionally, L-Sox5 and Sox6 are required for the development of chondroblasts [40].
Both Sox factors L-Sox5 and Sox6 are co-expressed with Sox9 during chondrogenesis
except for the period prior to mesenchymal condensation verified by experiments with
Sox5sox6 double mutants demonstrating normal mesenchymal condensations but no
chondrogenesis [10, 40]. All three Sox proteins are required for the differentiation of
chondroblasts to chondrocytes [14]. L- Sox5 and Sox6 belong to subgroup D and share a
similar sequence in their coiled-coil region forming homo- or hetero-dimers [4].
Dimerization of L- Sox5 and Sox6 facilitates their binding to the first intron of Col2a1.
They share the common HMG domain with Sox9 [41]. As neither L-Sox5 nor Sox6 have
a transcription activation domain, they act as architectural factors that do not influence
the transcriptional activity but can indirectly modulate gene activity [42].
L-Sox5, Sox6, and Sox9 recognize HMG binding sites on Col2a1 and Aggrecan, the
major structural proteoglycan found in the ECM of cartilage. Collagen type II, the major
protein of the cartilage, contains a 48 bp sequence in its first intron, which contains 4
binding sites for Sox proteins [12]. Sox proteins can bind to Col2a1 and Aggrecan,
enhancing their expression [12]. Similarly, HMG binding sites have been identified on
Col11a2 that can be recognized by Sox9 [39, 43, 44]. Computational analyses have also
identified seven conserved pairs of HMG binding domains in the promoter region of
Col11a1 in both humans and mice, which could further show a relationship between
Sox9 activity and collagen type XI [45]. Recent EMSA studies have determined true
Sox9 binding sites on Col11a1 [46]. However, to date, regulation of Col11a1 expression
by Sox9 has not been demonstrated. One possibility is that the growth factors mediating
expression of cartilage-specific extracellular matrix proteins may do so through the
activity of Sox family transcription factors.

Regulation of chondrogenesis
Binding of L-Sox5, Sox6, and Sox9 to Col2a1 promotes the assembly of a multiprotein
enhancer complex and activates the basal transcriptional machinery required for
chondrogenesis (11). L-Sox5, Sox6, and Sox9 regulate transcription in chondrogenesis
using a cyclic-AMP (cAMP) response element-binding (CREB) protein mediated by
DNA acetylation [37]. Sox9 activity can be regulated by multiple factors. For instance,
Smad3 increases the interaction between Sox9 and CREB-Binding Protein (CBP/p300),
which in turn increases Sox9 transcriptional activity [47]. Similarly, proliferation
activated receptor gamma co-activator 1-alpha (PGC1-α) co-activates Sox9 during
chondrogenesis [48]. The interaction between Sox9 and thyroid hormone receptorassociated protein 230/Med12 (TRAP) also significantly increases Sox9 transcriptional
activity [49]. Since Col11a1 and Col11a2 both contain multiple Sox9 binding sites, it is
possible that the same transcriptional machinery may be used to regulate their expression
in cartilage (Figure 4). Further studies are required to verify the role for Sox9 in Col11a1
and Col11a2 expression. Sox9 expression is regulated by many growth factor signaling
pathways. For instance, FGFs use the Mitogen Activated Protein (MAP) pathway to
increase Sox9 expression in chondrocytes and mesenchymal cells. Both chondrocytes and
mesenchymal cells express FGF receptors [50]. Likewise, PTHrP increases cAMP levels
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and phosphorylates Sox9 by activating the Protein Kinase A (PKA) pathway in vivo [51].
Phosphorylation of Sox9 enhances its activity and leads to increased Col2a1 expression
in the prehypertrophic zone of the growth plate [51] (Figure 4).

Figure A4. Sox9 protein has highly conserved high mobility group (HMG)
domain and sites of phosphorylation. The HMG domain is a conserved domain (amino
acids 101-184) within human (H. sapiens), mouse (M. musculus), rabbit (O. cuniculus)
and zebrafish (D. rerio). Serine 181 (S181) and serine 184 (S211) are PTHrP dependent
sites of phosphorylation on Sox9. Sequence logo was generated using WebLogo 3.0 [54,
55].
Both Sox9 and PTHrP prevent proliferating chondrocytes from becoming hypertrophic
[45]. As a result, cartilage is conserved and bone formation is inhibited. Inhibited
differentiation of proliferating chondrocytes into hypertrophic chondrocytes could
alternatively be due to the lack of ECM components as suggested by Akiyama. Indeed,
mice lacking Col11a1 show premature ossification [5] (Figure 2B). Col11a1 binds to
heparin sulfate proteoglycans and through this interaction may facilitate FGF signaling
that is dependent on heparan sulfate [52, 53]. FGF can subsequently stimulate
chondrogenesis via Sox9 activation. Similarly, Sox9, PTHrP, and Col11a1 all show
similar or overlapping effects in preventing chondrocytes from becoming hypertrophic
and thus mineralizing. It is notable to mention that pre-hypertrophic chondrocytes express
Sox9 and the PTHrP receptor [46]. Extracellular matrix may modulate PTHrP-mediation
of chondrogenesis and the transition from proliferative chondrocyte to hypertrophic
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chondrocyte. Alternatively, PTHrP may induce changes in the expression of extracellular
matrix molecules that are critical for the formation of cartilage. To date, the analysis of
PTHrP-mediated changes during skeletal development has not included an analysis of the
minor fibrillar collagens. It is possible that minor fibrillar collagens in the ECM bind to
PTHrP or alternatively to its receptor and regulate the PTHrP pathway, acting upstream
of the cellular signaling pathway during chondrogenesis. Studies on the regulation of
PTHrP-Sox mediated chondrogenesis may provide us with a better understanding of the
molecular mechanism of craniofacial development.

CONCLUSION
The role of minor fibrillar collagens V/XI in L-Sox5, Sox6, and Sox9-mediated
chondrogenesis and the interaction with growth factors that provide external cues during
craniofacial development is a relatively new area of investigation. Since the cartilage
abnormalities in Col11a1 cho/cho mice, and Col11a1 zebrafish mutants are similar to
those induced in Sox9 mutant mice and zebrafish, and PTHrP-deficient mice, an
investigation of the interaction between these molecular constituents may provide
fundamental information. Studies are needed to look at the role of PTHrP in Soxmediated chondrogenesis and the relationship to minor fibrillar collagens. The
multipotency of NCCs is of great interest to basic science as well as to the development
of regenerative medicine approaches for the treatment of skeletal injuries. Understanding
the interplay between minor fibrillar collagens, Sox proteins, and PTHrP in NCC-derived
structures could explain the multiple levels of regulation of chondrogenesis and thus
proper cartilage formation during craniofacial development of the embryo. The results
could help us understand the mechanism by which minor fibrillar collagens regulate
chondrogenesis as well as how minor fibrillar collagens are regulated during this process.
Having a better understanding of the mechanisms by which chondrogenesis and cartilage
formation occur may provide us with new tools to diagnose and prevent disorders of the
craniofacial skeleton including cleft palate and osteochondrodysplasias in utero.
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